Introduction
Gene delivery into human blood cells has been explored as a means to correct or protect against genetic alterations in a variety of human diseases such as congenital enzyme deficiencies or hematological malignancies. 1 Various gene transduction systems have been developed, the most widely investigated of which is the murine leukemia virus (MLV) vector system, but human blood cell transduction efficiency has been uniformly low. [2] [3] [4] [5] We have demonstrated previously that a novel allosterically controllable ribozyme, designated the Maxizyme, induces cell death in a chronic myelogenous leukemia (CML) cell line harboring the b2a2 type bcr-abl oncogene in vitro 6 and in vivo, 7 but we could not efficiently transduce Maxizyme into primary cells of leukemia patients. The lack of efficient gene transduction techniques has so far hampered efforts to provide gene therapy for hematological disorders. Several studies have demonstrated that second-generation vesicular stomatitis virus (VSV)-G glycoprotein-pseudotyped human immunodeficiency virus type 1 (HIV-1) based (HIV(VSV)) vectors have relatively high transduction efficiencies in primary human ALL and AML blasts (40-90%) 8 and human CD34 + cord blood progenitors (4279%). 9 These vectors, however, could not be used to transduce genes efficiently into resting human PBLs (4.870.7%). 10 In this study, to improve transduction and integration efficiency and prevent vector-induced toxicity and the generation of replication-competent lentivirus, we have tested a third-generation HIV(VSV) vector that contains the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) 4, 11 and the central DNA flap sequence. [12] [13] [14] Additionally, we developed a new self-inactivating (SIN) VSV-pseudotyped MLV (MLV(VSV)) vector harboring the same promoter as the SIN HIV(VSV) vector to remove the interference of the LTR, and compared the gene transduction efficiencies of these vectors in human leukemia cells, peripheral blood lymphocytes (PBLs) and cord blood hematopoietic cells. Our results demonstrate highly efficient gene transduction mediated by the third-generation SIN HIV(VSV) vector compared with the SIN MLV(VSV) vector.
Results

Gene transduction of leukemia and myeloma cells with HIV or MLV vector
A total of 10 leukemia or myeloma cell lines and 11 primary cell samples obtained from leukemia or myeloma patients (Table 1) were transduced with equivalent titers of HIV(VSV) or MLV(VSV) vector harboring a humanized Renilla reniformis green fluorescent protein (GFP) marker gene ( Figure 1 ) at a multiplicity of infection (MOI) of 40. After 3 days, these cells were observed by fluorescence microscopy and flow cytometry (FCM) to detect GFP expression. In the K562 CML cell line, almost all cells were successfully transduced with HIV(VSV) vector, but only 46% were with the MLV(VSV) vector (Figure 2a ). Transduction efficiencies of the HIV(VSV) and MLV(VSV) vectors in the majority of the other cell lines were almost 100% and less than 50%, respectively ( Figure 2b ). To confirm these results, several important issues were clarified. First, to eliminate the possibility that the higher GFP expression in cells transduced with the HIV(VSV) vector was because of the WPRE sequence, which has been reported to enhance gene expression at the post-transcriptional level, we tested an MLV(VSV) vector containing the WPRE sequence (MLV-PRE(VSV)) ( Figure 1b) . As we could only obtain low titers of the MLV-PRE(VSV) vector, the cells described above were transduced at an MOI of 20. As shown in Figure 2c , the WPRE sequences did not modulate GFP expression when placed in the MLV SIN vector used here. Second, another possible reason for the high transduction efficiency of the HIV(VSV) vector could have been that the transducible titers of these vectors were not accurately represented by the amount of vector genome. Since the differences in GFP expression levels might have had an impact on the determination of the vector titers using HeLa cells, we determined the DNA titers, which are known to reflect the amount of transducible vector genome, by real-time PCR as reported previously. 15 We then examined transduction Figure 1 Schematic diagrams of lentiviral and retroviral constructs. (a) The four constructs used to produce the third-generation SIN HIV(VSV) vector. pCS-CDF-ChG-PRE, pMDLg/p.RRE, pRSV-rev, and pMD.G indicate the HIV-based transfer vector, packaging plasmid, rev expression plasmid and VSV G-protein expression plasmid, respectively. (b) The three constructs used to produce the SIN MLV(VSV) or SIN MLV-PRE(VSV) vector. pMS-ChG or pMS-ChG-PRE, pSV-C À -env À -MLV and pMD.G indicate the MLV-based transfer vector, packaging plasmid and VSV G-protein expression plasmid, respectively. Abbreviations are as follows: CMV, cytomegalovirus promoter; LTR, long terminal repeat; C, packaging signal; SD, splice donor; SA, splice acceptor; RRE, Rev-responsive element; R, repeat region; DU3, promoter/enhancer sequence-deleted U3 (shown as hatched box); cPPT, central polypurine tract; CTS, central termination sequence; hrGFP, humanized Renilla reniformis green fluorescent protein; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; pA, poly A; RSV, respiratory syncytial virus promoter; DATG, deletion of start codon; SV40, simian virus 40 promoter; and C À , deletion of packaging signal. The DNA titers for the HIV vector were approximately five times higher than the GFP titers, while the DNA titers for the MLV(VSV) vectors were only 1.5 times higher than the GFP titers. Therefore, transduction of the MLV(VSV) vector at an MOI of 20 and that of the HIV(VSV) vector at an MOI of 6 based on GFP titers are comparable when the titers were calculated based on the DNA titers. Transduction efficiencies with the HIV(VSV) vector at an MOI of 6 were slightly lower than those at an MOI of 20, but both of them were higher than those with the MLV(VSV) vectors at an MOI of 20 ( Figure 2c ). As for primary cells, we demonstrated that more than 70% of cells were transduced with the HIV(VSV) vector in 10 of the 11 primary cell types, whereas less than 60% of the cells were transduced with the MLV(VSV) vector in a majority of the cell types ( Figure 3) . Irrespective of the target cell, the transduction efficiencies obtained with our HIV vector were always higher than those obtained with the MLV vector. These results are compatible with a previous report in which a few kinds of acute lymphoblastic leukemia (ALL) cells were examined. 5 Interestingly, the fluorescence intensity of the cells transduced with the HIV vector was higher, indicating a higher level of GFP expression, than those transduced with the MLV vector (Figures 2a and 3a) . Transduction efficiencies with both vectors were slightly lower when conducted with an MOI of 4 compared with an MOI of 40, but the HIV vector was still consistently more efficient than the MLV vector (data not shown).
Long-term gene expression in leukemia and myeloma cells transduced with the HIV vector
To evaluate the stability of transgene expression with HIV(VSV) and MLV(VSV) vectors, we analyzed GFP expression in leukemia cell lines transduced with these vectors by FCM at several time points up to 8 weeks. The expression level of GFP in K562, MEG-01, NB4, C8166, and IM-9 cells transduced with the HIV vector at an MOI of 40 was maintained at 90-100% of the initial value over the time course of examination ( Figure 4 ). In addition, the transduction efficiencies were maintained at almost the same level even after the MOI of the HIV(VSV) vector was reduced to 20 or 6 (Figure 4c ). Similar results were obtained in the other five cell lines (data not shown). Since almost 100% of HIV(VSV)-transduced cells became GFP positive, we also determined the mean fluorescence intensity (MFI) of these cells. The MFI of these cells Chromosomal DNA from transduced colonies was subjected to two rounds of PCR amplification, with the first pair of primers complementary to the 3 0 end of the chromosomal Alu repeat sequence and the 3 0 HIV or MLV long terminal repeat (LTR) as shown in Figure 6c . The amplified products, encompassing fragments between the 3 0 LTR transferred to the 5 0 end of integrated vectors and a nearby Alu sequence, were then further amplified using a second pair of primers targeting a nested LTR sequence in each vector (Figure 6c ). The second round of PCR resulted in the generation of a 298-bp (HIV) or 308-bp (MLV) product, which could be detected by Southern blotting using an LTR-specific probe for the HIV or MLV vector (Figure 6c and d) . 
Gene transduction of PBLs
As is done in assays for leukemia cells, 2 Â 10 5 PBLs were stimulated with PHA or simply maintained in culture without stimulation and transduced with HIV(VSV) or MLV(VSV) vector at an MOI of 40. After transduction, PHA-stimulated PBLs were cultured in the presence of interleukin-2 (IL-2) for 7 days, whereas unstimulated cells were cultured in the absence of any cytokines. At 7 days after transduction, average transduction efficiencies with the HIV or MLV vector in activated PBLs from seven healthy volunteers were 86 and 19%, respectively ( Figure  7a ). In unstimulated PBLs, the mean transduction efficiencies were 39% with the HIV vector and less than 10% with the MLV vector (Figure 7a ). These results were comparable with previous reports on stimulated PBLs transduced with a second-generation HIV(VSV) vector However, the transduction efficiency in unstimulated PBLs obtained with our HIV vector was higher than previously seen using a second-generation vector. 10 To evaluate the relation between gene transduction efficiencies of PBL subsets and their activation state, we examined the expression of GFP, CD4, CD8, and activation markers including CD25, CD38, and CD69 [20] [21] [22] in PBLs transduced with HIV vectors. The majority of stimulated PBLs expressed the activation markers, and GFP expression was slightly higher (Table 2, Figure 7b ). Almost all unstimulated PBLs were negative for CD25 and CD69, and about 40% were also negative for CD38, indicating that the majority of these cells are in the resting state. GFP expression was confirmed in all cells (Table 2, Figure 7b ). Finally, we compared the transduction efficiency in different PBL subsets and, as shown in Table 2 , transduction efficiencies in CD4-or CD8-positive cells were at the same level regardless of prior PHA stimulation.
Gene transduction of cord blood CD34 + hematopoietic cells
Since transduced hematopoietic cells may be used for gene therapy in many disease indications, including hematopoietic disorders, we examined the gene transduction efficiency of HIV(VSV) and MLV(VSV) vectors in CD34 + hematopoietic cells. We obtained more than 95% pure human cord blood CD34 + cells that had not been stimulated with any cytokines prior to transduction. The CD34 + cells were transduced with the HIV or MLV vector at an MOI of 40 or 80, followed by culture with or without stem cell factor (SCF), interleukin-3 (IL-3), and interleukin-6 (IL-6). As shown in Figure 8a , 96% of CD34 + cells cultured with the cytokines expressed GFP on day 2 when the cells were transduced with the HIV vector at an MOI of 80. GFP was expressed in CD34 + cells and also CD13 + differentiated cells on day 8. To compare the transduction efficiencies of HIV and MLV vectors, we examined GFP expression of CD34 + cells cultured with or without the cytokines described above. In this assay, cells were transduced with both vectors at an MOI of 40. Both the cytokine-stimulated HIV and MLV vector-transduced cells expressed GFP, although the transduction efficiency with the MLV vector was lower (Figure 8b ). In the absence of cytokine stimulation, the same tendency was observed, although the overall transduction efficiency in both cell groups was lower (Figure 8b ). We also examined the transduction efficiencies of the HIV(VSV), MLV(VSV), and MLV-PRE(VSV) vectors at an MOI of 20. The transduction efficiency of each vector was slightly lower than at an MOI of 40, and the addition of the WPRE sequence to the MLV(VSV) vector did not enhance transgenic expression (data not shown).
Gene transduction and integration into colonies derived from cord blood hematopoietic cells
To evaluate transduction in progenitor cells, cord blood CD34 + cells were transduced with HIV or MLV vector, as was done for leukemia cells. All of the colonies derived from HIV(VSV)-vector transduced cells expressed GFP, and the expression levels in the BFU and CFU-GEMM colonies were higher than in CFU-GM colonies ( Figure  9a and b) . In contrast, almost all colonies transduced with the MLV(VSV) or MLV-PRE(VSV) vector did not express detectable GFP (Figure 9a and b) . All colonies were positive for GFP DNA, whether or not the initial cells had been transduced with the HIV or MLV vector (Figure 9b and c) , suggesting that the transmission efficiencies, but not integration efficiencies, of both VSV-pseudotyped vectors are at a similar level. We could detect by Alu-PCR a positive integration band in 97% of colonies derived from cells transduced with HIV vectors, but less than 5% of MLV(VSV) or MLV-PRE(VSV) vector-transduced colonies were integration positive (Figure 9b and c) . The Alu-PCR-positive colonies transduced with the HIV vector always expressed GFP, but those with MLV vectors expressed GFP only at trace levels (Figure 9b ). These results suggest that the 
Discussion
Recently, it has been reported that VSV-pseudotyped lentiviral vectors, such as HIV(VSV) vectors, are suitable for gene transduction into human blood cells. 2, 8, 10 For clinical applications, however, HIV vectors must satisfy the strictest safety requirements, because of the nature of the parental virus. 23 To achieve a high level of biosafety and ensure patient safety, we used a third-generation packaging system where not only the tat gene is deleted, but also the Rev protein is expressed from a separate nonoverlapping expression plasmid (Figure 1a ). 24 Furthermore, we used an SIN transfer vector to decrease the potential for the production of replication-competent lentivirus (Figure 1a) , resulting in Tat-independent virus production. 25 These modifications not only increase the safety of HIV vector-mediated gene therapy but also reduce cytotoxicity associated with lentiviral vector infection by deleting the proapoptotic Tat protein. 26 Several reports have demonstrated that second-generation HIV(VSV) vectors are capable of highly efficient gene transduction in human blood cells, including primary leukemia cells from B-precursor ALL (2.2-43.35%), 5 ALL (40.3-90.3%), and AML (61.7-87.6%) patients. 8 These HIV vectors were also reported to exhibit higher transduction efficiencies than MLV vectors. 5 The intact LTR of MLV, however, is known to interfere with the internal promoter inserted into the vector 27 that was used in this study. To compare the differences in gene transduction efficiency between HIV and MLV vectors, we used comparable functional titers (GFP and DNA expression titers) of vectors comprising the same envelope protein and internal promoter with a self-inactivation system. In almost all leukemia or myeloma cell lines, primary cells from leukemia or myeloma patients, PBLs, and CD34 + hematopoietic cells, transduction efficiency was much higher with the HIV vector than with the MLV vector. The superiority of the HIV vector was similar to that seen in previous reports; the high transduction efficiency of the HIV vector in resting PBLs, however, was quite surprising.
Unlike other retroviral vectors such as MLV-based vectors, lentiviral vectors offer significant advantages for stable long-term transgenic expression. No evidence of transcriptional inactivation has been reported up to 9 months after lentiviral gene transfer into a wide spectrum of target tissues. 23 The central DNA flap sequence of HIV-1 is an important component in a late step of viral genome nuclear import, and insertion of this sequence into lentiviral vectors increases transduction efficiency by restoring to wild-type levels the nuclear import that is defective in the original vector DNA. 12 Moreover, recent studies have demonstrated that reinsertion of the DNA flap sequence in an HIV-derived lentiviral vector strikingly increases gene transduction efficiency in human CD34 + hematopoietic cells 13 and primary T-lymphocytes.
14 WPRE has also been reported recently to enhance transgene expression through posttranscriptional regulation in the vectors. 4 Hence, we speculate that the high integration efficiency obtained with the third-generation lentiviral vectors in our experiments is made possible by the central DNA flap and the WPRE insertion.
Early steps of retroviral infection involve entry of the viral core into cells, reverse transcription of the viral RNA genome to yield a linear cDNA copy, and integration of the resulting cDNA copy into a chromosome of the host cell. 28 The unintegrated retroviral cDNA can also follow a nonproductive pathway leading to loss of the viral genome, in which circularization takes place by ligation of the LTR sequences (2-LTR circle), homologous recombination between LTRs (a single LTR circle), or integration of the viral cDNA into itself, yielding internally rearranged circular forms. 29 Over a long-term observation period, we observed a rapid decrease in GFP expression in cells transduced with the MLV vector (Figures 4 and 5) . Although long-term transgenic expression is strictly dependent on stable integration of the gene into the chromosome of host cells, it was reported that the expression of an integrated gene introduced by MLV vector transduction decreased over time. 30 Some studies demonstrated that the mechanism of retroviral inactivation is associated with de novo methylation of viral sequences, especially in the LTR. 31 In our studies, we detected a few colonies expressing GFP at a low level. These colonies were transduced with the MLV SIN vectors and were demonstrated to harbor integrated vector DNA, suggesting that a silencing mechanism might have been triggered (Figures 6 and  9 ). Several reports, however, have suggested another mechanism for the silencing of virally expressed genes, 32 and we have demonstrated that the decreased gene expression with the MLV vector used here is primarily because of the low efficiency of proviral DNA integration into the chromosome of the host cells (Figures 6 and 9) . In MLV vector-transduced CD34 + cell-derived colonies, the number of GFP DNA-positive colonies was higher than that in K562 cell-derived colonies. This could be because of the difference in culture time after gene transduction, which was 14 days for CD34
+ cord blood cells and 28 days for K562 cells (Figures 6 and 9) . These results suggest that many transgenes in the MLV SIN vector had disappeared without integration as cells replicated. In addition, the obscure effect of WPRE sequence in MLV SIN vector-transduced cells is probably because of insufficiently high integration efficiency and GFP expression to demonstrate any substantial effect. Alternatively, WPRE activity could have been inhibited in the MLV SIN vector by an unknown mechanism. These results might provide a more general explanation for the unstable expression of transgenes delivered by MLV vectors.
In conclusion, we have demonstrated that our thirdgeneration SIN lentiviral vector can deliver genes at high efficiencies to a wide variety of human blood cells and integrate the transgenes into the host genome, resulting in stable expression. In contrast, even if the titer of the MLV vector is enhanced by VSV-G pseudotyping, gene integration efficiency is still low and long-term transgenic expression in target cells is rare. This is the first report to compare VSV-G pseudotyped SIN type HIV and MLV vectors in different hematopoietic cell types, further 
Materials and methods
Cell lines
Human cervical carcinoma cell line HeLa cells were cultured in Eagle's minimal essential medium supplemented with 10% FBS. 293T cells, a human embryonic kidney cell line transduced with simian virus 40 Tantigen, were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS. The human myeloid leukemia cell lines used in this study were the acute promyelocytic leukemia (APL) lines NB4 (kindly provided by Dr M Lanotte, Hopital Saint-Louis, Paris, France) 33 and HL60 (provided by American type culture collection (ATCC), Rockville, MD, USA), and the acute myelogenous leukemia M2 (AML-M2) line IMS-M2, 34 provided by Dr F Nagamura (Institute of Medical Science, University of Tokyo, Tokyo, Japan). Chronic myelogenous leukemia-blastic crisis (CML-BC) cell lines K562 and MEG-01 were obtained from ATCC, and BV173 cells were provided by Hayashibara Biochemical Laboratories, Inc, (Okayama, Japan). 35 The Philadelphia chromosome-positive ALL cell line OM9;22 was supplied by Dr K Ohyashiki (Tokyo Medical College, Tokyo, Japan), 36 and the human multiple myeloma (MM) cell lines IM-9 and HS-Sultan were obtained from ATCC. These leukemia and myeloma cell lines were cultured in RPMI 1640 medium (RPMI) supplemented with 10% FBS. Adult T-cell leukemia (ATL) cell line C8166 was obtained and cultured as described previously. 37 
Primary leukemia or myeloma cells
Primary leukemia and myeloma cells were obtained from peripheral blood (PB), bone marrow (BM), or pleural effusion (PE) and used for the following experiments after obtaining informed consent from each patient. These cells were purified by Ficoll-Hypaque centrifugation and frozen in liquid nitrogen until assay. Cell characteristics are listed in Table 1 . At 1 day before transduction, cells were thawed and cultured in RPMI with 10% FBS, and for myeloid cells only, 25 ng/ml of SCF (provided by Amgen, Thousand Oaks, CA, USA), 10 ng/ml of IL-3 (provided by Chugai Pharmaceuticals Co. Ltd, Tokyo, Japan), and 100 ng/ml of IL-6 (provided by Ajinomoto Co. Inc.) were added to the medium.
Preparation of PBLs
PB mononuclear cells were isolated from healthy volunteers by Ficoll-Hypaque centrifugation and cultured in RPMI 1640 medium with heat-inactivated 5% human type AB serum at 371C. After 24 h of culture, cells were stimulated with 10 mg/ml of PHA for 3 days, or simply maintained in the medium for 3 days before gene transduction.
Preparation of CD34
+ cells.
Umbilical cord blood samples were collected from healthy volunteers after obtaining informed consent. Samples were stored for less than 24 h at 41C with heparin sulfate before mononuclear cells were isolated using the Ficoll-Hypaque method as described above.
Purification of CD34 + cells was performed using a MACS direct CD34 progenitor cell isolation kit (Miltenvi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The final sample of CD34 + cells was more than 95% pure.
Construction and production of lentiviral and retroviral vectors
Production of MLV-and HIV-derived vectors pseudotyped with the VSV-G proteins was achieved by transient cotransfection of four (HIV) or three (MLV) plasmids into 293 T cells. The design of these plasmid constructs is drawn schematically in Figure 1 . The SIN HIV vector plasmid pCS-CDF-ChG-PRE contains the humanized R. reniformis GFP (hrGFP) marker gene driven by the CMV promoter. The hrGFP gene was isolated from the phrGFP-N1 vector (Stratagene, La Jolla, CA, USA) by polymerase chain reaction (PCR)-based amplification and subcloned into a previously described HIV vector containing central DNA flap sequence of HIV-1 and the WPRE. 25 The HIV-derived packaging construct used was pMDLg/p.RRE (provided by Cell Genesys, Foster City, CA, USA), which contains the HIV-1 gag and pol genes, but none of the accessory (vif, vpr, vpu, and nef) or tat genes. 24 The regulatory protein Rev and VSV-G protein were expressed by pRSV-rev. 24 and pMD.G, respectively (Figure 1a) . For the production of MLV SIN vector particles, the following plasmids were cotransfected to 293T cells according to previous report:
38 a pSV-C À -env À -MLV packaging plasmid (generous gifts of Dr DR Littman, New York University School of Medicine, New York, NY, USA) 39 and a pMS-ChG transfer vector in which the 3 0 LTR enhancer-promoter region of pMX had been deleted 40 (kindly provided by Dr T Kitamura, University of Tokyo, Japan). Into this plasmid were inserted the CMV promoter and hrGFP gene in tandem in the multicloning site and pMD.G (Figure 1b) . To generate the MLV-PRE(VSV) vector, we constructed the pMS-ChG-PRE plasmid as follows. The WPRE sequence cassette was excised from the pCS-CDF-ChG-PRE with XhoI and ClaI, and inserted into pMS-ChG at the XhoI and SalI sites downstream of the GFP stop codon ( Figure  1b ). This plasmid was cotransfected into 293T cells with the same packaging plasmid and VSV-G plasmid as was used for the MLV(VSV) vector. The transfection protocol was scaled up to make use of the 6320 cm 2 Nunc cell factory (Nalge Nunc International, Rochester, NY, USA), with a calcium phosphate transfection kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). The medium was replaced with fresh culture medium after 12 h. Viral supernatants were harvested 48 and 72 h after transfection, passed through 0.22 mm filters (Millipore, Bedford, MA, USA), and concentrated by two rounds of ultracentrifugation. The viral pellet was resuspended in serum-free Iscove's modified Dulbecco's medium resulting in a final concentration ratio of 2000-fold for the HIV(VSV) vector and 20 000-fold for the MLV(VSV) vector. Viral stocks were stored at À801C until assay, and viral vector titers were determined by transduction of HeLa cells with serial dilutions and following FCM in a range from 2 Â 10 8 to 4 Â 10 9 HeLa-transducing units per milliliter (GFP titers). The DNA expression titers (DNA titers) were determined by the real-time PCR method reported previously. 15 Probe and primer sequences are as 
Inoculation of viral vectors
Human blood cells (2 Â 10 5 ) obtained as described above were inoculated with the HIV or MLV vector for 2 h at 371C in a CO 2 incubator. After inoculation, leukemia or myeloma cells were washed and cultured in RPMI with 10% FBS. For primary myeloid leukemia cells, culture medium was supplemented with 25 ng/ml SCF, 10 ng/ ml IL-3, and 100 ng/ml IL-6, and for primary myeloma cells, 100 ng/ml IL-6 was added. For PBLs, cells were cultured after transduction in the medium described above, supplemented with 50 U/ml IL-2 for PBL stimulation. CD34 + hematopoietic cells were cultured in RPMI medium supplemented with 10% serum substitute BIT 9500 (Stem Cell Technologies, Vancouver, Canada) with or without 25 ng/ml SCF, 10 ng/ml IL-3, and/or 100 ng/ml IL-6 after transduction. A fraction of the transduced K562, MEG-01 (100 cells) was used for colony formation assay and cultured in Iscove's modified DMEM, containing 30% FBS, 1% bovine serum albumin, 1.2% methylcellulose, from days 14 to 28 after transduction. For CD34
+ cord blood cells, 500 cells were plated in the same semisolid media as described above but with the following hematopoietic factors: 25 ng/ml SCF, 10 ng/ml IL-3, 100 ng/ml IL-6, 10 ng/ml granulocytecolony-stimulating factor (G-CSF), and 2 U/ml erythropoietin (EPO) (G-CSF and EPO were provided by Chugai Pharmaceuticals Co. Ltd).
Detection of transgene expression
Gene transduction was analyzed by observing GFPexpressing cells and individual colonies under an inverted fluorescence microscope, and determining transduction efficiencies by FCM using a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Four-color FCM for PBL analysis was performed using the following fluorescence-labeled antibodies (Becton Dickinson Pharmingen, San Diego, CA, USA): PE-labeled anti-CD25, PE-labeled anti-CD38, PE-labeled anti-CD69, PerCP-labeled anti-CD4, and APC-labeled anti-CD8. For cord blood hematopoietic cells, we examined CD34 or CD13 expression by two-color FCM using PE-labeled anti-CD34 antibody (Beckman Coulter, Anaheim, CA, USA) or PE-labeled-CD13 antibody (Becton Dickinson Pharmingen).
PCR analysis of transgenes in colonies from K562, MEG-01, and CD34
+ cord blood cells
On day 14 of the colony formation assay, each colony derived from either leukemia cells or CD34 + cord blood cells was picked up, and half of the cells were transferred into 0.5 ml tubes containing 18 ml of lysis buffer (10 mM Tris-HCl, 50 mM KCl, and 400 mg/ml proteinase K), followed by incubation for 5 min at 551C and inactivation for 5 min at 961C. The amount of DNA subjected to PCR was normalized by the intensity of b-globin bands detected after PCR. To detect the hrGFP and b-globin (control) genes, PCR was performed on the cell lysate using AmpliTaq Gold DNA polymerase (Applied Biosystems, Branchburg, NJ, USA) and the following PCR primers in a final volume of 20 ml with 40 cycles of thermal cycling at 961C for 30 s, 611C for 30 s and 721C for 1 min. PCR primer sequences are as follows: hrGFP, 5 0 -GTGGAGATCCGCAGCGACATCAACCT-3 0 (sense, the 325th to 350th) and 5 0 -GCTGTTCAGGCGGTACAC-CAGGATCAC-3 0 (antisense, 493rd to 519th); and human b-globin, 5 0 -GGGCAAGGTGAACGTGGATGA-3 0 (sense, the 227th to 247th) and 5 0 -CCATCACTAAAGGCACC-GAGC-3 0 (antisense, the 513th to 533rd). PCR products were subjected to 2% agarose gel electrophoresis and Southern blotting with a 98-bp nucleotide probe (the 348th to 446th of hrGFP), as described below.
Detection of integrated vector DNA in colonies derived from K562, MEG-01, and CD34
To detect integration of proviral DNA, but not unintegrated forms, we carried out Alu-LTR PCR as described previously (Figure 6c ). Primers used for the first PCR are as follows: Alu-3 0 as sense primer (5 0 -TCCCAGCTACTCGGGAGGCTGAGG-3 0 , the 164th to 187th of human Alu consensus sequence), HIV-U3 as antisense primer for the HIV vector (5 0 -AGGCAAGCTT TATTGAGGCTTAAGC-3 0 , the 516th to 540th of HIV-1 LTR), and MLV-U3 as antisense primer for the MLV vector (5 0 -GCAACTGCAAGAGGGTTTATTGGATACA CG-3 0 , the 487th to 516th of MLV LTR). The same cell lysate, which was prepared for PCR for transgene detection as described above, was amplified with AmpliTaq Gold DNA polymerase. The amount of DNA subjected to PCR was normalized as described above. Samples were first denatured at 961C for 9 min and then amplified by 35 cycles of thermal cycling at 961C for 1 min, 551C (HIV) or 581C (MLV) for 1 min, and 721C for 2.5 min, with a final 10 min extension at 721C. Following the first PCR, a second PCR was carried out using 1 ml of the first PCR product. Nested primers for the second PCR are as follows: HIV-1 LTR, 5 0 -CACACACAAGGC TACTTCCCT-3 0 (sense, the 57th to 77th) and 5 0 -TCCCAGGCTCAGATCTGGTCT-3 0 (antisense, the 468th to 488th); and MLV LTR, 5 0 -AATGAAAGACCC CACCTGTAGGTTTGG-3 0 (sense, the 1st to 27th) and 5 0 -TACCCGGGCGACTCAGTCAATC-3 0 (antisense, the 463rd to 481st). The reaction conditions involved an initial denaturation at 961C for 9 min followed by 20 cycles of thermal cycling at 961C for 30 s, 551C (HIV) or 571C (MLV) for 30 s, and 721C for 1 min, with a final 10 min extension at 721C. As negative control reactions, colony genomic DNA from untransduced cells was amplified by Alu-PCR. To obtain expected band sizes, pCS-CDF-ChG-PRE or pMS-ChG-PRE diluted in colonyderived genomic DNA was amplified directly by the second PCR. Following Alu-PCR, 5 ml samples were electrophoresed in 2% agarose gels, transferred to Hybond-N+ nylon membranes (Amersham Pharmacia Biotech), and hybridized with an HIV (229 bp, the 112th to 340th of 3 0 LTR of pCS-CDF-ChG-PRE) or MLV LTRspecific (272 bp, the 31st to 302nd of 3 0 LTR of pMS-ChG) oligonucleotide probe labeled with thermostable alkaline phosphatase. Probe labeling, hybridization, signal generation, and detection were performed using the Gene Images AlkPhos Direct labeling and detection system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
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